Why investors ponied up $76M for this company's new approach to Alzheimer's
May 31, 2018 at 11:09 AM EDT
Leaders of this 12-person company say their experimental drug, which will enter a mid-stage clinical trial next year, attacks a specific bacteria at the root of Alzheimer's inflammation and protein tangles in the brain.
